Human macrophages and dendritic cells can equally present MART-1 antigen to CD8+ t cells after phagocytosis of gamma-irradiated melanoma cells

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Barrio, María Marcela ^a   Abes, Riad ^b,c   Colombo, Marina ^d   Pizzurro, Gabriela ^a   Boix, Charlotte ^b,c   Roberti, María Paula ^a   Gélizé, Emmanuelle ^b,c   Rodriguez Zubieta, Mariana ^d   Mordoh, José ^a,d   Teillaud, Jean Luc ^b,c  

^a Fundación Cáncer FUCA Centro de Investigaciones Oncológicas   (Argentina)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA A ANTIGEN; MELAN A; HLA A*02:01 ANTIGEN; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN; MLANA PROTEIN, HUMAN;

ANTIBODY AFFINITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL FATE; CELL PHAGOCYTOSIS; CELL SPECIFICITY; COCULTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENDRITIC CELL; GAMMA IRRADIATION; HLA SYSTEM; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; MACROPHAGE ACTIVATION; MELANOCYTE; MELANOMA; TUMOR CELL CULTURE; BIOSYNTHESIS; GAMMA RADIATION; GENE EXPRESSION REGULATION; IMMUNOLOGY; MACROPHAGE; METABOLISM; PHAGOCYTOSIS; RADIATION EXPOSURE; TUMOR CELL LINE;

ALEXA;

ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA-A2 ANTIGEN; HUMANS; INTERFERON-GAMMA; MACROPHAGES; MART-1 ANTIGEN; MELANOMA; MICROSCOPY, CONFOCAL; PHAGOCYTOSIS;

EID: 84863619846     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040311     Document Type: Article

References (53)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
2. Coulie PG, Brichard V, van Pel A, Wölfel T, Schneider J, et al. (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180: 35-42.
3. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, et al. (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 91: 3515-3519.
4. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, et al. (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 91: 6458-6462.
5. Brichard V, van Pel A, Wölfel T, Wölfel C, de Plaen E, et al. (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178: 489-495.
6. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA, (1996) Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 184: 2207-2216.
7. van der Bruggen P, Traversari C, Chomez P, Lurquin C, de Plaen E, et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647.
8. Hoashi T, Watabe H, Muller J, Yamaguchi Y, Vieira, et al, (2005) MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes. J Biol Chem 280: 14006-14016.
9. Slingluff CL Jr, Petroni GR, Olson W, Czarkowski A, Grosh WW, et al. (2008) Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 26: 4973-4980.
10. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, et al. (2006) DC study group of the DeCOG: Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17: 563-570.
11. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, et al. (2009) Dendritic cell vaccination combined with CTLA-4 blockade in patients with metastatic melanoma. Clin Cancer Res 15: 6267-6276.
12. Speiser DE, Pittet MJ, Guillaume P, Lubenow N, Hoffman E, et al. (2004) Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J Immunother 27: 298-308.
13. Mordoh J, Kairiyama C, Bover L, Solarolo E, (1997) Allogeneic cells vaccine increases disease - free survival in stage III human melanoma patients: A non randomized Phase II Study. Medicina 57: 421-427.
14. Barrio MM, de Motta PT, Kaplan J, von Euw EM, Bravo AI, et al. (2006) A Phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. J Immunother 29: 444-454.
15. Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, et al. (2003) Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol 171: 5940-5947.
16. Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, et al. (2006) Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 29: 545-557.
17. von Euw EM, Barrio MM, Furman D, Bianchini M, Levy EM, et al. (2007) Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8+ T lymphocytes. J Transl Med 5: 19 doi:10.1186/1479-5876-5-19.
18. Banchereau J, Steinman RM, (1998) DCs and the control of immunity. Nature 392: 245-352.
19. Banchereau J, Palucka AK, (2000) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 1: 387-391.
20. Amigorena S, Savina A, (2010) Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr Opin Immunol 22: 109-117.
21. Moehler MH, Zeidler M, Wilsberg V, Cornelis JJ, Woelfel T, et al. (2005) Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum Gene Ther 16: 996-1005.
22. Russo V, Tanzarella S, Dalerba P, Rigatti D, Rovere P, et al. (2000) Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sci U S A 97: 2185-2190.
23. Motta I, André F, Lim A, Tartaglia J, Cox WI, et al. (2001) Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J Immunol 167: 1795-1802.
24. Gaipl US, Beyer TD, Baumann I, Voll RE, Stach CM, et al. (2003) Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal - implications for antiphospholipid syndrome and systemic lupus erythematosus. Immunobiology 207: 73-81.
25. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL, (1993) Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A 90: 4942-4946.
26. Pozzi LA, Maciaszek JW, Rock KL, (2005) Both dendritic cells and macrophages can stimulate naïve CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J Immunol 175: 2071-2081.
27. Brayer J, Cheng F, Wang H, Horna P, Vicente-Suarez I, et al. (2010) Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunol Lett 131: 126-130.
28. Olazabal IM, Martín-Cofreces NB, Mittelbrunn M, Martinez del Houo G, Alarcon B, et al. (2008) Activation outcomes induced in naïve CD8 T cells by macrophages primed via phagocytic and nonphagocytic pathways. Mol Biol Cell 19: 701-710.
29. Asano K, Nabeyama A, Miyake Y, Qiu CH, Kurita A, et al. (2011) CD169-positive macrophages dominate antitumor immunity by cross presenting dead cell-associated antigens. Immunity 34: 85-95.
30. Mac Keon S, Gazzaniga S, Mallerman J, Bravo AI, Mordoh J, et al. (2010) Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue. Vaccine 28: 8162-8168.
31. Soule HD, Vazguez J, Long A, Albert S, Brennan M, (1973) A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1416.
32. Bover L, Barrio M, Slavutsky I, Bravo AI, Quintans C, et al. (1991) Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor. Breast Cancer Res Treat 19: 47-56.
33. Boyer A, Andreu G, Romet-Lemonne JL, Fridman WH, Teillaud JL, (1999) Generation of phagocytic MAK and MAC-DC for therapeutic use: characterization and in vitro functional properties. Exp Hematol 27: 751-761.
34. von Euw EM, Barrio MM, Furman D, Levy EM, Bianchini M, et al. (2008) A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10-1082 promoter genotype as predictor of disease progression. J Transl Med 6: 6 doi:10.1186/1479-5876-6-6.
35. Baron-Bodo V, Doceur P, Lefebvre ML, Labroquère K, Defaye C, et al. (2005) Anti-tumor properties of human-activated macrophages produced in large scale for clinical applications. Immunobiol 210: 267-277.
36. Guerra L, Mordoh J, Slavutsky I, Larripa I, Medrano EE, (1989) Characterization of IIB-MEL-J: a new and highly heterogenous human melanoma cell line. Pigment Cell Res 2: 504-509.
37. Vély F, Gruel N, Moncuit J, Cochet O, Rouard H, et al. (1997) A new set of monoclonal antibodies against human Fc gamma RII (CD32) and Fc gamma RIII (CD16): characterization and use in various assays. Hybridoma 16: 519-528.
38. Beatty JD, Beatty BG, Vlahos WG, (1987) Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods 100: 173-179.
39. Chen YT, Stockert E, Jungbluth A, Tsang S, Coplan KA, et al. (1996) Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci U S A 93: 5915-5919.
40. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD, (1999) Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 162: 2227-2234.
41. de Mazière AM, Muehlethaler K, van Donselaar E, Salvi S, Davoust J, et al. (2002) The melanocytic protein Melan-A/MART-1 has a subcellular localization distinct from typical melanosomal proteins. Traffic 3: 678-693.
42. Steinman RM, Banchereau J, (2007) Taking dendritic cells into medicine. Nature 449: 419-426.
43. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, et al. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332.
44. Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, et al. (2011) Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother 60: 249-260.
45. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, et al. (2004) In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 199: 815-824.
46. Sancho D, Mourão-Sá D, Joffre OP, Schulz O, Rogers NC, et al. (2008) Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 118: 2098-2110.
47. Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, et al. (2010) Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood 116: 2277-2285.
48. Vingert B, Adotevi O, Patin D, Jung S, Shrikant P, et al. (2006) The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol 36: 1124-1135.
49. Blachère NE, Darnell RB, Albert ML, (2005) Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol 3: e185 doi:10.1371/journal.pbio.0030185.
50. Brusa D, Garetto S, Chiorino G, Scatolini M, Migliore E, et al. (2008) Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. Vaccine 26: 6422-6432.
51. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, et al. (2000) Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191: 423-434.
52. Thiounn N, Pages F, Mejean A, Descotes JL, Fridman WH, et al. (2002) Adoptive immunotherapy for superficial bladder cancer with autologous macrophage activated killer cells. J Urol 168: 2373-2376.
53. Monnet I, Breau JL, Moro D, Lena H, Eymard JC, et al. (2002) Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study. Chest 121: 1921-1927.